Lenacapavir, a twice yearly injection that prevents HIV transmission, was named the breakthrough medicine of 2024. But without US foreign aid dollars, its delivery to millions worldwide is under ...

Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...

Infections with the hepatitis E virus often go unnoticed because they cause no symptoms. However, in patients with a weakened ...

The Zika virus builds tiny tunnels, called tunneling nanotubes, to stealthily transport material needed to infect nearby ...

This involves the HIV-1 protease (a viral enzyme), that cuts up Gag into six smaller proteins including the capsid protein and the matrix protein. This causes a huge structural rearrangement of ...

Latus’ other lead gene therapy uses its AAV-Ep+ capsid to target ependymal cells as well as neurons. Ependymal cells secrete proteins into the cerebrospinal fluid. Co-opting this function ...

The dengue virus has a roughly spherical structure. It is composed of the viral genome and capsid proteins surrounded by an envelope and a shell of proteins. After infecting a host cell ...

Lenacapavir 463.5mg/1.5mL (309mg/mL); soln for SC inj; preservative-free. Lenacapavir is a multistage, selective inhibitor of HIV-1 capsid function that directly binds to the interface between ...